Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Debt for 8 consecutive years, with $13.8 million as the latest value for Q2 2023.

  • On a quarterly basis, Non-Current Debt fell 39.09% to $13.8 million in Q2 2023 year-over-year; TTM through Jun 2023 was $13.8 million, a 39.09% decrease, with the full-year FY2022 number at $17.8 million, down 9.59% from a year prior.
  • Non-Current Debt was $13.8 million for Q2 2023 at Cartesian Therapeutics, down from $16.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $25.0 million in Q1 2022 to a low of $6.4 million in Q2 2020.
  • A 4-year average of $20.0 million and a median of $21.3 million in 2021 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: surged 255.57% in 2021, then plummeted 39.09% in 2023.
  • Cartesian Therapeutics' Non-Current Debt stood at $24.8 million in 2020, then dropped by 20.65% to $19.7 million in 2021, then decreased by 9.59% to $17.8 million in 2022, then decreased by 22.48% to $13.8 million in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Non-Current Debt are $13.8 million (Q2 2023), $16.2 million (Q1 2023), and $17.8 million (Q4 2022).